Skip to main content

Table 1 Overview of expert characteristics

From: Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia

Expert characteristics

N = 7 (%)

Years treating patients with pALL

 5–10

2 (29%)

 10–20

3 (43%)

 21+

2 (29%)

Approximate number of r/r pALL patients seen per month

 1–5

3 (29%)

 6–10

1 (29%)

 11–20

1 (14%)

 21+

2 (29%)

Number of patients the expert has treated with any CAR T-cell therapy

 1–5

2 (29%)

 6–10

2 (29%)

 11–15

1 (14%)

 25+

2 (29%)

Number of patients the expert has treated with tisagenlecleucel

 0

1 (14%)

 1–5

3 (43%)

 6–10

1 (14%)

 11–15

2 (29%)

  1. pALL pediatric acute lymphoblastic leukemia, CAR chimeric antigen receptor, r/r relapsed/refractory